Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.
Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.
复制标题
DOI：
10.1099/0022-1317-75-8-2075
复制
发表时间：
1994-08
期刊：
影响因子：
--
通讯作者：
R. Rose;R. Reichman;W. Bonnez
中科院分区：
文献类型：
--
作者：
R. Rose;R. Reichman;W. Bonnez
我们测试了重组人乳头瘤病毒11型（HPV-11）病毒样颗粒（vlp）诱导形成中和抗体的能力，并在ELISA中测试了与HPV-11全病毒粒子的血清诊断能力。从ac11l1感染的Sf9悬浮细胞培养物的无细胞上清中，用CsCl密度梯度离心纯化vlp，用于免疫家兔，并在HPV-11感染的胸腺小鼠模型中检测抗vlp抗体。用vlp处理动物的免疫血清预处理感染性HPV-11病毒粒子，可显著降低移植物生长（P < 10(-4)）和病毒基因表达（P < 10(-4)），与使用全病毒粒子刺激后血清获得的效果相似，与免疫中和一致。为了评估VLP的血清诊断能力，开发了VLP ELISA，并用于分析以前用HPV-11全病毒粒子ELISA检测的血清。在49%的患者血清中检测到特异性抗体（P = 2 × 10(-4)），个体VLP血清活性与先前使用全病毒粒子作为抗原获得的血清活性相关（r = 0.87; P < 10(-6)）。这些结果表明，重组VLPs可以引起中和抗体反应，并且可以在hpv血清诊断免疫测定中忠实地替代天然病毒粒子。
Recombinant human papillomavirus type 11 (HPV-11) virus-like particles (VLPs) were tested for their ability to induce the formation of neutralizing antibodies, and were also tested for serodiagnostic capabilities in an ELISA in comparison with HPV-11 whole virions. VLPs, purified by CsCl density gradient centrifugation from the cell-free supernatant of Ac11L1-infected Sf9 suspension cell cultures, were used to immunize rabbits and anti-VLP antibodies were tested in the athymic mouse model of HPV-11 infection. Pretreatment of infectious HPV-11 virions with the immune serum of VLP-treated animals caused a marked reduction of graft growth (P < 10(-4)) and viral gene expression (P < 10(-4)), similar to the effects obtained using whole virion postimmune serum, and consistent with immune neutralization. To assess the serodiagnostic capabilities of VLPs, a VLP ELISA was developed and used to analyse sera that were tested previously in an HPV-11 whole virion ELISA. Specific antibodies were detected in 49% of patients' sera (P = 2 x 10(-4)), and individual VLP seroreactivities correlated with those previously obtained using whole virions as the antigen (r = 0.87; P < 10(-6)). These results indicate that recombinant VLPs can be used to elicit a neutralizing antibody response, and can substitute faithfully for native virions in the development of HPV-serodiagnostic immunoassays.